LMAT:NSD-LeMaitre Vascular Inc. (USD)

EQUITY | Medical Instruments & Supplies | NASDAQ Global Market

Last Closing

USD 65.46

Change

+2.47 (+3.92)%

Market Cap

USD 0.44B

Volume

0.12M

Analyst Target

USD 34.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

LeMaitre Vascular Inc provides medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-26 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ISRG Intuitive Surgical Inc

+5.60 (+1.46%)

USD 133.13B
COO The Cooper Companies Inc.

+1.02 (+1.10%)

USD 19.60B
HOLX Hologic Inc

+0.17 (+0.22%)

USD 17.83B
RGEN Repligen Corporation

-0.32 (-0.19%)

USD 9.30B
XRAY Dentsply Sirona Inc

N/A

USD 6.35B
MMSI Merit Medical Systems Inc

+0.93 (+1.17%)

USD 4.28B
AZTA Azenta Inc

-0.22 (-0.40%)

USD 3.09B
ICUI ICU Medical Inc

+1.06 (+1.05%)

USD 2.31B
STAA STAAR Surgical Company

+0.67 (+1.46%)

USD 2.31B
ATRC AtriCure Inc

-0.23 (-1.04%)

USD 1.06B

ETFs Containing LMAT

RNSC First Trust Small Cap US .. 2.73 % 0.60 %

+0.05 (+0.16%)

USD 0.03B
EWO iShares MSCI Austria ETF 0.00 % 0.47 %

+0.20 (+0.16%)

USD 0.06B

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 15.33% 86% B+ 82% B
Dividend Return 0.28% 20% F 16% F
Total Return 15.61% 86% B+ 81% B-
Trailing 12 Months  
Capital Gain 21.22% 84% B 77% C+
Dividend Return 1.07% 67% D+ 14% F
Total Return 22.30% 84% B 77% C+
Trailing 5 Years  
Capital Gain 125.65% 96% N/A 87% B+
Dividend Return 7.91% 80% B- 30% F
Total Return 133.56% 96% N/A 88% B+
Average Annual (5 Year Horizon)  
Capital Gain 22.50% 75% C 81% B-
Dividend Return 23.63% 75% C 82% B
Total Return 1.13% 83% B 29% F
Risk Return Profile  
Volatility (Standard Deviation) 37.79% 55% F 48% F
Risk Adjusted Return 62.54% 95% A 87% B+
Market Capitalization 0.44B 78% C+ 77% C+

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Instruments & Supplies) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 44.40 39% 20%
Price/Book Ratio 5.05 20% 22%
Price / Cash Flow Ratio 40.93 20% 7%
Price/Free Cash Flow Ratio 28.95 18% 8%
Management Effectiveness  
Return on Equity 10.64% 88% 77%
Return on Invested Capital 9.79% 84% 79%
Return on Assets 7.07% 89% 91%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.